NASDAQ:TWSTTwist Bioscience Stock Price, Forecast & News

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TWST stock has increased by 120.9% and is now trading at $62.29.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Twist Bioscience.

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Twist Bioscience.

Twist Bioscience will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Twist Bioscience Corp (NASDAQ:TWST) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.85) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.10. The business had revenue of $19.30 million for the quarter, compared to analysts' expectations of $17.18 million. Twist Bioscience had a negative return on equity of 71.31% and a negative net margin of 222.66%. Twist Bioscience's revenue was up 41.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.93) EPS.
View Twist Bioscience's earnings history.

2 analysts have issued 12-month price targets for Twist Bioscience's stock. Their forecasts range from $42.00 to $42.00. On average, they expect Twist Bioscience's share price to reach $42.00 in the next twelve months. This suggests that the stock has a possible downside of 32.6%.
View analysts' price targets for Twist Bioscience.

Media coverage about TWST stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Twist Bioscience earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near future.
View the latest news about Twist Bioscience.

Some companies that are related to Twist Bioscience include Novavax (NVAX), Repligen (RGEN), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), bluebird bio (BLUE), Sorrento Therapeutics (SRNE) and Fate Therapeutics (FATE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include Canopy Growth (CGC), Gilead Sciences (GILD), Square (SQ), AbbVie (ABBV), Aurora Cannabis (ACB), Amarin (AMRN), Arcturus Therapeutics (ARCT), Alibaba Group (BABA), Inovio Pharmaceuticals (INO) and Iovance Biotherapeutics (IOVA).

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Twist Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.38%), Emerald Advisers LLC (1.13%), Emerald Mutual Fund Advisers Trust (1.02%), Essex Investment Management Co. LLC (0.25%), Conestoga Capital Advisors LLC (0.09%) and Quantitative Systematic Strategies LLC (0.06%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green and William Banyai.
View institutional ownership trends for Twist Bioscience.

TWST stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, SG Americas Securities LLC, Emerald Mutual Fund Advisers Trust, and Arizona State Retirement System. Company insiders that have sold Twist Bioscience company stock in the last year include Bill Peck, Emily M Leproust, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green, and William Banyai.
View insider buying and selling activity for Twist Bioscience.

TWST stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Essex Investment Management Co. LLC, Conestoga Capital Advisors LLC, Quantitative Systematic Strategies LLC, and ProShare Advisors LLC.
View insider buying and selling activity for Twist Bioscience.

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TWST stock can currently be purchased for approximately $62.29.

Twist Bioscience has a market capitalization of $2.55 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.

The official website for Twist Bioscience is www.twistbioscience.com.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]